tbuckley/cabot-search huggingface dataset:
Abstract 4365: A cellular model for investigation of circulating tumor cells and identification of therapeutic target and regimen
Authors: Yao-Wen Chang, Kowit-Yu Chong, Pei-Yun Lin, Pei-Wen Hsieh, Chang-Hui Liao, Ching-Ping Tseng
Journal: Cancer Research (2012)

Abstract Tumor cells disseminating into circulatory system is crucial for cancer metastasis during cancer progression and surgical operation in removing tumor mass. Due to technical hurdles, it is not yet available to culture and propagate circulating tumor cells derived from cancer patients. Not yet any model system has been established to investigate the cellular and molecular changes associate with the entry of primary tumor cells into bloodstream. In this study, genetically modified C6 glioma cells (C6-LG) that elicit high procoagulant activity and express luciferase/GFP reporter gene were used for xenograft injection into nude mice to establish a metastatic model. Two C6-derived sublines, C6-lung and C6-blood, were isolated and established from the cells that colonized at lung tissue and from blood circulation, respectively. Cellular analyses revealed that C6-lung and C6-blood had differential cell cycle distribution, cell growth rate, migration and metastatic potential. Microarray analyses also revealed differential gene expression signatures between these two sublines. Nevertheless, podoplanin was up-regulated in both cell lines when compared to the parental C6-LG. Consistent with these observations, C6-lung and C6-blood activated platelet and induced platelet aggregation that is closely associated with their in vivo metastatic potential as revealed by gene knockdown analysis. Using these C6-sublines as the cellular screening platform, we have identified a novel compound designated as CGU-07 that elicited inhibitory activity in cancer cell-induced platelet aggregation. In conclusion, circulating and primary tumor cells have both common and distinguished cellular and molecular profiles. Targeting on the common molecular signature such as podoplanin raises the hope to further application of its therapeutic use in the prevention and treatment of tumor metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4365. doi:1538-7445.AM2012-4365
Penicillin in Treatment of Diphtheria
Authors: M. N. De, J. R. Chatterjee, L. Ganguli
Journal: BMJ (1947)

An epidemic of diphtheria in adults has been described, notable for the short duration of symptoms before admission.Difficulties of diagnosis have been discussed and the results of a short sdries of cases treated with penicillin have been given.We are indebted to the Director of Medical Services for permission to publish this paper.We wish to thank Brig.
AB0296 Discontinuation of tocilizumab after attaining remission in patients with rheumatoid arthritis
Authors: A. Nampei, Y. Nagayama
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Efficacy and safety of biologic agents against refractory rheumatoid arthritis (RA) patients have been proved, however expensive cost is still a serious problem. Biologic free study about infliximab (RRR study) and adalimumab (HONOR study) were reported, but study about tocilizumab (TCZ) is none. <h3>Objectives</h3> To investigate the maintenance ratio of biologic free, low disease activity (LDA), remission (REM) after discontinuation of TCZ in RA patients who had achieved REM <h3>Methods</h3> One hundred and fifteen RA patients have been treated by TCZ in our institution after 2008 Jury. Among them, patients, who had achieved DAS-REM (DAS28ESR&lt;2.6) by TCZ treatment and maintained DAS-REM over six months, and who discontinued TCZ by patients’ hope, were selected retrospectively. The ratio of biologic free, LDA, REM after discontinuation of TCZ were calculated by Kaplan Meier method. Related factor between the patients’ group who were flared arthritis and the patients’ group who could maintain disease activity were analyzed by logistic regression test. <h3>Results</h3> Ten patients discontinued TCZ after remission by patients’ hope. All patients were bio-naïve patients and TCZ was used as first-bio. Average age was 53(25-69), average disease duration were 4.3 years (0.9-15.5), and average DAS28ESR was 1.5(0.5-1.8) at the point of TCZ discontinuation. Average duration of TCZ treatment was 86.2 weeks. Methotrexate user was 8 patients (4-10mg/wk) and predonisolone user was 3 patients (1-5mg/day). Arthritis flared to four patients over LDA at 15, 18, 22, 84 weeks after TCZ discontinuation respectively. Two patients restarted TCZ at 31 weeks, and 49 weeks after discontinuation of TCZ and clinical REM could be achieved soon, while another two patients did not restart TCZ. The maintenance ratio of biologic free was 100% (24wk), 53.3% (52wk). The maintenance ratio of LDA, and REM was 85.7%, 67.5% (24wk), and 45.7%, 33.8% (52wk) respectively. Significant related factor between flare group and maintenance group was not recognized. <h3>Conclusions</h3> The maintenance ratio of LDA and REM after discontinuation of TCZ was low compared with previously reported biologic free study of TNF-inhibitor<sup>1) 2)</sup>. This study was retrospective and number was small, further investigation will be needed. <h3>References</h3> Tanaka Y et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 69: 1286-1291, 2010 Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol. 24: 319-326, 2012 <h3>Disclosure of Interest</h3> None Declared
Abstract 51: Stromal AKT2 controls epithelial invasions
Authors: Ann-Christin Cichon, Adam Pickard, Daksha Patel, Dennis McCance
Journal: Cancer Research (2012)

Abstract The tumor microenvironment is gaining importance in the regulation of tumorigenesis, invasion and metastasis. Loss of PTEN, a negative regulator of AKT, in stromal fibroblasts results in an increased tumor occurrence in ErbB2 expressing murine mammary tumors. Furthermore, we have shown that activation of AKT in stromal fibroblasts, following loss of the Retinoblastoma Protein (Rb), induces epithelial invasions in organotypic raft cultures, via an increase in Keratinocyte Growth Factor (KGF) expression. In addition, we have shown that loss of the PTEN tumor suppressor in stromal fibroblasts and subsequent activation of AKT, increases invasive potential of Human Papilloma Virus Type 16 E6 and E7 expressing keratinocytes. This is mediated by an increase in KGF expression. There are three isoforms of AKT expressed in human fibroblasts, AKT1, AKT2 and AKT3. By depleting each individual AKT isoform in stromal fibroblasts we have been able to establish that AKT2 is essential in regulating the cross talk between epithelium and stroma, and depletion of stromal AKT2 inhibits invasions. However, loss of stromal AKT2 does not function exclusively through regulation of KGF levels as it activates a second, protective pathway, which is able to counteract the effects of KGF. This protective pathway is mediated by increased Interleukin1 beta levels produced by the fibroblasts. Preliminary data from head and neck cancer specimens show that AKT is activated in stroma of cells associated with tumor but not normal tissue. Future work will determine the AKT dependent pathways that lead to increased KGF and Interleukin1 beta expression as well as how these factors mediate invasions. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 51. doi:1538-7445.AM2012-51
1338 NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH HIGHER OBJECTIVELY MEASURED SEDENTARY BEHAVIOUR AND LOWER LEVELS OF PHYSICAL ACTIVITY THAN MATCHED HEALTHY CONTROLS
Authors: K. Hallsworth, C. Thoma, S. Moore, T. Ploetz, Q.M. Anstee, C.P. Day, M.I. Trenell
Journal: Journal of Hepatology (2013)
The Body-Mass Index of Twins Who Have Been Reared Apart
Authors: Albert J. Stunkard, Jennifer R. Harris, Nancy L. Pedersen, Gerald E. McClearn
Journal: New England Journal of Medicine (1990)

To assess the relative importance of genetic and environmental effects on the body-mass index (weight in kilograms divided by the square of the height in meters), we studied samples of identical and fraternal twins, reared apart or reared together. The samples consisted of 93 pairs of identical twins reared apart, 154 pairs of identical twins reared together, 218 pairs of fraternal twins reared apart, and 208 pairs of fraternal twins reared together.
Sunlight and Risk of Uveal Melanoma
Authors: E. P. Horn, P. Hartge, J. A. Shields, M. A. Tucker
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Sunlight and Risk of Uveal Melanoma Get access Erich P. Horn, Erich P. Horn Howard Hughes Medical Institute, Bethesda, Md., and Epidemiology and Biostatistics Program, National Cancer InstituteBethesda Search for other works by this author on: Oxford Academic PubMed Google Scholar Patricia Hartge, Patricia Hartge Epidemiology and Biostatistics Program, National Cancer Institute Search for other works by this author on: Oxford Academic PubMed Google Scholar Jerry A. Shields, Jerry A. Shields Oncology Service, Wills Eye HospitalPhiladelphia, Pa Search for other works by this author on: Oxford Academic PubMed Google Scholar Margaret A. Tucker Margaret A. Tucker Epidemiology and Biostatistics Program, National Cancer Institute Correspondence to : Margaret A. Tucker, Chief. Genetic Epidemiology Branch, EPN 439, 6130 Executive Blvd., Rockville, MD 20892. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 19, 5 October 1994, Pages 1476–1478, https://doi.org/10.1093/jnci/86.19.1476 Published: 05 October 1994 Article history Received: 13 July 1994 Accepted: 19 July 1994 Published: 05 October 1994
Gynecology in the Community
Authors: Lewis C. Scheffey
Journal: New England Journal of Medicine (1947)

SOME years ago a colleague of mine in a western city told me that whenever he was asked to speak on the subject of "office gynecology," he refused, because he did not believe that there was such a thing. I heartily disagree with his concept, for I think that the office of the general practitioner is often — but not always — the original source of much good for the patient.Recently, Thompson and Thompson,1 of Camden, Arkansas, presented many points worthy of cognizance and reflection, and their paper is recommended to those who have not read it. I acknowledge . . .
USE-PAAF COMBINADO CON CITOMETRIA DE FLUJO EN EL DIAGNÓSTICO DE PACIENTES CON SOSPECHA DE LINFOMA
Authors: C Consiglieri Alvarado, JB Gornals Soler, C Pons Vilardell, F Climent Esteller, N Baixeras Gonzalez, R Llatjos Sanuy, E De La Banda Ledrado, I Catala Costa
Journal: Endoscopy (2013)

Introducción: existe aún poca información sobre la utilidad de la USE-PAAF en el diagnóstico de procesos linfoproliferativos. Objetivo: evaluar la utilidad de la USE-PAAF combinada con la citometria de flujo (CF) en el diagnóstico de patologia linfoproliferativa. Material y métodos: revisión retrospectiva de la base de datos de nuestro centro de pacientes con sospecha de linfoma por detección de lesiones y/o adenopatias abdominales o mediastínicas por pruebas de imagen previas. Agujas utilizadas: 22G, 19 G y Trucut. Citometria de flujo- estudio inmunofenotipico- en casos de muestra suficiente. Diagnóstico final confirmado por USE-PAAF, otras biopsias y seguimiento clínico. Resultados: en 17 pacientes (4 H, 13 M; 60,6 ± 3,2 años) se realizó punción guiada por USE para el estudio de enfermedad linfoproliferativa. En 7 se diagnosticó de limfoma (2 limfoma Hodgkin, 5 no-Hodgkin, 1 enfermedad de Castleman o EC), 6 casos asociados patologia benigna diversa (1 tuberculosis, 1 enfermedad de Whipple, 4 ganglios inflamatorios reactivos), 2 asociados a malignidad (1 sarcoma, 1 timoma). Hubo 2 casos de muestra insuficiente y en uno, el diagnóstico final de limfoma requirió de biopsia radiológica en 1 caso. Un caso diagnósticado de limfoma, requirió biopsia quirúrgica para tipificación del subtipo. Se describió un falso negativo, catalogado como linfadenitis reactiva y con diagnostico final de EC por biopsia quirúrgica. No se detectó ningún falso positivo. La sensibilidad, especificidad, valor predictivo positivo y negativo, y la precisión diagnóstica de la USE-PAAF en el diagnóstico de limfoma fueron 85,7%, 100%, 100%, 88,8% y 93,3% respectivamente. Conclusiones: La ecoendoscopia con punción ofrece muestras óptimas y con elevada precisión diagnóstica en el estudio citohistológico de pacientes con sospecha de linfoma.
OC-151 Prevalence of, and predictors of, a positive SEHCAT scan for bile acid diarrhoea in outpatients with chronic diarrhoea
Authors: D J Gracie, F Chowdhury, J Kane, S Mumtaz, A C Ford
Journal: Gut (2012)

<h3>Introduction</h3> SeHCAT scanning is not commonly performed in patients with chronic diarrhoea, despite British Society of Gastroenterology guidelines advocating its use. Greater awareness of bile acid diarrhoea (BAD) may increase uptake of testing. We aimed to assess the prevalence of BAD in consecutive patients with chronic diarrhoea undergoing SeHCAT scanning, and to identify factors predicting a positive result. <h3>Methods</h3> A retrospective review was undertaken over 6 years at Leeds Teaching Hospitals. A standardised scanning protocol was adopted. Medical records were reviewed to obtain information regarding previous cholecystectomy, terminal ileal (TI) Crohn9s disease (CD), TI resection or right hemicolectomy for CD, right hemicolectomy for other reasons, radiation exposure, enteric infection and microscopic colitis. BAD was defined as present when SeHCAT retention was &lt;15% (mild &lt;15%, moderate &lt;10%, and severe &lt;5%), and classified according to underlying aetiology (type I secondary to TI resection or right hemicolectomy, type II idiopathic, and type III secondary to all other causes). Presence of bloating and abdominal pain were used to define IBS. <h3>Results</h3> 163 (51.4%) of 317 patients had some degree of BAD. A greater proportion of patients with a positive test had undergone cholecystectomy (29.4% vs 13.9%, p=0.001), TI resection for CD (17.8% vs 1.9%, p&lt;0.001) or TI resection or right hemicolectomy for other reasons (8.6% vs 1.9%, p=0.009). Radiotherapy, enteric infection, or microscopic colitis were not associated with BAD. 54 (37%) of 145 individuals with no obvious risk factors had some degree of BAD, with 17 (32.1%) having severe BAD. Fewer individuals with BAD reported bloating (16.0% vs 25.0%, p=0.05), and fewer met criteria for IBS (40.5% vs 52.6%, p=0.03). More patients with severe disease had previous right hemicolectomy or TI resection for CD (32.1%, p&lt;0.001). A greater proportion of those with mild BAD fulfilled criteria for IBS, compared with those with moderate or severe BAD (65.9% vs 46.3% and 24.7%, p&lt;0.001). <h3>Conclusion</h3> BAD is common in patients with chronic diarrhoea. Prior surgery is a strong predictor of a positive test, and may negate need for testing. However, among those with no proposed risk factors, yield of testing was almost 40%. The prevalence of BAD in patients with chronic diarrhoea is high, and SeHCAT scanning is a worthwhile diagnostic strategy. <h3>Competing interests</h3> None declared.
AGE DIFFERENCES IN ELECTROMECHANICAL PROPERTIES OF THE LEFT ATRIUM ASSESSED WITH ADVANCED ECHOCARDIOGRAPHY IN PATIENTS WITH NO STRUCTURAL HEART DISEASE
Authors: Rachid Abou, Melissa Leung, Tomaz Podlesnikar, Nina Ajmone Marsan, Victoria Delgado, Jeroen Bax
Journal: Journal of the American College of Cardiology (2016)
CHANGES IN THE FIBROUS CAP THICKNESS COVERING LIPID POOL AFTER DRUG ELUTING STENT IMPLANTATION - OCT STUDY
Authors: Tomoya Ueda, Shiro Uemura, Yoko Dote, Yutaka Goryo, Yu Sugawara, Satoshi Okayama, Makoto Watanabe, Yoshihiko Saito
Journal: Journal of the American College of Cardiology (2015)
Prognosis in Hyaline-Membrane Disease
Authors: Mildred T. Stahlman, Edward J. Battersby, Frank M. Shepard, Willard J. Blankenship
Journal: New England Journal of Medicine (1967)

THE pathological diagnosis of hyaline-membrane disease is made at autopsy in approximately 30 per cent1 of infants who die in the neonatal period. The characteristic pathological changes are found in 40 to 60 per cent of infants whose birth weight is less than 2500 gm. Although the diagnosis in surviving infants cannot be established by any pathognomonic clinical or laboratory feature, or any combination of features, a clinical, biochemical and radiological pattern is usually characteristic enough to be separable from other causes of respiratory distress in newborn infants. A wide range of severity occurs among infants with this clinical syndrome. . . .
Abstract 161: Plasma-based biomarkers for breast cancer diagnosis
Authors: Zhibin Hu, Hongbing Shen, Jing Dong, Hongxia Ma, Juncheng Dai, Qingyi Wei, Li-E Wang
Journal: Cancer Research (2011)

Abstract Introduction It has been demonstrated that there are abundant, stable microRNAs (miRNAs) in plasma/serum, which can be detected and is potentially disease-specific. In this study, we aimed to assess whether serum/plasma miRNAs may be used as potential biomarkers for breast cancer diagnosis. Methods We used systematically Solexa sequencing as well as TaqMan Low Density Array followed by individual quantitative reverse transcription polymerase chain reaction assays to screen plasma miRNAs in 48 breast cancer patients and 48 age-matched controls of Chinese origin for the discovery stage and validated in an internal validation set (50 patients and 50 controls in Chinese) and in an external validation set (24 patients and 24 controls in Caucasians). Results Four miRNAs (miR-16, miR-25, miR-222 and miR-324-3p) were differentially expressed between breast cancer cases and controls and subsequently validated in the internal and external validation stage samples. Taken together, Chinese patients with high plasma miRNA expression levels had a significantly increased risk of breast cancer for all the four miRNAs. The Area Under the Receiver Operating Characteristic Curve was 0.917 for the four-miRNA signature in the discovery stage (sensitivity=0.917 and specificity=0.917), 0.930 in the internal validation stage (sensitivity=0.920 and specificity=0.940). Conclusions The four-miRNA signature from plasma may serve as a noninvasive diagnostic biomarker for breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 161. doi:10.1158/1538-7445.AM2011-161
AB0246 Prevalence and risk factors of preclinical carotid atherosclerosis in patients with rheumatoid arthritis
Authors: N. Nikitina, A. Rebrov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The principal cause of death in patients with rheumatoid arthritis (RA) is the cardiovascular disease (CVD) associated with atherosclerosis. To improve the prognosis of living in RA patients an early diagnostics of atherosclerosis which lies in the base of it is necessary. <h3>Objectives</h3> The aim of this study is to estimate the intima-media thickness (IMT) of carotid arteries in RA patients depending on the degree of coronary risk. Doppler sonography of carotid arteries was performed in 110 patients with RA and 20 healthy individuals. Evaluation of fatal complication on a SCORE scale was performed; the overall risk of coronary heart disease (total coronary risk) was calculated. <h3>Results</h3> In RA patients, there is markedly increased prevalence of preclinical atherosclerosis compared to control. In 49 (44, 6%) patients with RA thickening of the intima-media complex has been revealed. In 19 (17,3%) patients atherosclerotic plaque was detected. The IMT dependence on the traditional risk factors is found. At the same time in the absence of the traditional risk factors the features of the course of RA (the presence of systemic manifestations, RA duration, and systemic inflammation severity) contribute to increased carotid IMT, especially in young patients. In RA patients, plaque presence is associated with age, high SCORE. <h3>Conclusions</h3> Thus, the presence of RA can be considered as a separate RF of atherosclerosis development. Measurement of IMT in RA patients with moderate risk of fatal complications can be used for early diagnosis of atherosclerosis in RA patients. <h3>Disclosure of Interest</h3> None Declared
NT-20 * TARGETING CDK4 AND 6 IN THE CLASSICAL SUBTYPE OF GLIOBLASTOMA
Authors: D. Madani, S. Nixdorf, K. McDonald
Journal: Neuro-Oncology (2014)

BACKGROUND: Glioblastoma is highly refractory to conventional treatment approaches. Since the introduction of concomitant and adjuvant temozolomide and radiotherapy, patients with glioblastoma have shown little improvement in the median survival time of just 15 months. Inhibitors that target the cell cycle of the tumour present an exciting prospect for glioblastoma, in particular the classical subtype. Overexpression of the cyclin dependent kinases (CDK) 4 and 6 as well as the homozygous deletion of CDNK2A are common events in glioblastoma. MATERIALS AND METHODS: We have developed over 15 patient derived xenograft (PDX) models with whole genome sequencing data. We identified the PDX models (n = 4) that were of a "classical" subtype i.e. harbored mutations and amplification of EGFR, homozygous deletion of CDKN2A and wildtype for TP53 and RB1. We also measured the protein expression levels of CDK4/6 to confirm overexpression. We tested a highly specific and potent antiproliferative CDK4/6 inhibitor on this pre-selected panel of patient derived glioblastoma cells. We tested the efficacy of the CDK4/6 inhibitor as a monotherapy and in combination with radiotherapy (RT). Expression of CDK4 and 6 is also regulated by the microRNA (miRNA)-124a. Loss of miR-124a leads to the dysregulation of the CDK proteins and increased cell proliferation. Cells were transfected with miR-124a and then treated with the CDK4/6 inhibitor (+/- RT) to determine if efficacy is increased. RESULTS: We found, as a monotherapy, the CDK4/6 inhibitor to be highly effective in causing cell death on the pre-selected PDX cell lines (IC50: 5-15 µM). Increases in efficacy were observed when we combined the inhibitor with RT and when the cells were transfected with miR-124. In vivo analysis of the drug and in combination with RT and miR-124 are currently underway. CONCLUSION: This study presents a new potential clinical strategy for patients with classical glioblastoma.